Venous thromboembolism prophylaxis after major surgery for urological cancer: Are we prescribing it correctly?
BAUS ePoster online library. Henry M. 06/25/19; 265260; CU-7
Ms. Mei-Ling Henry
Ms. Mei-Ling Henry
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
Aims
This audit aimed to assess compliance with national guidance and ascertain current practice at a single centre for urology, regarding the prescription of mechanical and pharmacological thromboprophylaxis after major urological surgery for cancer.

Method
Retrospective data were collected for consecutive patients undergoing major abdominal surgery for urological cancer at a single centre for urology over a 31 day period using local electronic theatre management and prescribing systems. National guidelines for thromboprophylaxis were used to set criteria and standards.

Results
24 patients with a suspected or confirmed cancer diagnosis were operated over a 31 day period. 100.0% of patients had enoxaparin prescribed as an inpatient on their discharge summary (24/24). 58.3% of patients were prescribed 28 days of enoxaparin (14/24). 37.5% of patients had an alternative length of extended pharmacological prophylaxis, ranging from 27 to 31 days (9/24). 20.8% of patients were prescribed anti-embolism stockings as an inpatient and 16.7% of patient were prescribed anti-embolism stockings for discharge (4/24). When course length for anti-embolism stockings was specified on the discharge summary it was found to match the course length of the enoxaparin prescribed.

Conclusion
Excellent overall compliance with prescription of pharmacological thromboprophylaxis was identified, although mechanical thromboprophylaxis was highlighted as an area requiring improvement. A further cycle of data collection to collect data on instructions given in operative notes and results will be presented locally. Further to this a re-audit will be planned and is expected to be complete by June 2019.

INTRODUCTION
Venous thromboembolism (VTE) is an important cause of morbidity and mortality in patients admitted to hospital. The risk of developing VTE is affected by patient factors, such as co-morbidities and age, and admission related factors, such as surgical
Aims
This audit aimed to assess compliance with national guidance and ascertain current practice at a single centre for urology, regarding the prescription of mechanical and pharmacological thromboprophylaxis after major urological surgery for cancer.

Method
Retrospective data were collected for consecutive patients undergoing major abdominal surgery for urological cancer at a single centre for urology over a 31 day period using local electronic theatre management and prescribing systems. National guidelines for thromboprophylaxis were used to set criteria and standards.

Results
24 patients with a suspected or confirmed cancer diagnosis were operated over a 31 day period. 100.0% of patients had enoxaparin prescribed as an inpatient on their discharge summary (24/24). 58.3% of patients were prescribed 28 days of enoxaparin (14/24). 37.5% of patients had an alternative length of extended pharmacological prophylaxis, ranging from 27 to 31 days (9/24). 20.8% of patients were prescribed anti-embolism stockings as an inpatient and 16.7% of patient were prescribed anti-embolism stockings for discharge (4/24). When course length for anti-embolism stockings was specified on the discharge summary it was found to match the course length of the enoxaparin prescribed.

Conclusion
Excellent overall compliance with prescription of pharmacological thromboprophylaxis was identified, although mechanical thromboprophylaxis was highlighted as an area requiring improvement. A further cycle of data collection to collect data on instructions given in operative notes and results will be presented locally. Further to this a re-audit will be planned and is expected to be complete by June 2019.

INTRODUCTION
Venous thromboembolism (VTE) is an important cause of morbidity and mortality in patients admitted to hospital. The risk of developing VTE is affected by patient factors, such as co-morbidities and age, and admission related factors, such as surgical

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies